Breast cancer is a multifactorial disease and driven by aberrant regulation of cell signaling
pathways due to the acquisition of genetic and epigenetic changes. An array of growth …

Current standard-of-care (SOC) therapy for breast cancer includes targeted therapies such
as endocrine therapy for estrogen receptor-alpha (ERα) positive; anti-HER2 monoclonal …

Therapy resistance remains a huge challenge for current breast cancer treatments.
Exploring molecular mechanisms of therapy resistance might provide therapeutic targets for …

Non-coding RNAs (ncRNAs) have been implicated in most cellular functions. The disruption
of their function through somatic mutations, genomic imprinting, transcriptional and post …

Background Accumulating evidence has highlighted the potential role of RNA binding
proteins (RBPs) in the biological behaviors of glioblastoma cells. Herein, the expression and …

This paper concerns 3′-untranslated regions (3′ UTRs) of mRNAs, which are non-coding
regulatory platforms that control stability, fate and the correct spatiotemporal translation of …

Alternative polyadenylation (APA) is a molecular mechanism during a pre‐mRNA
processing that involves usage of more than one polyadenylation site (PA‐site) generating …

Unfolded protein response (UPR) signaling is activated under endoplasmic reticulum (ER)
stress, an emerging cancer hallmark, leading to either adaptive survival or cell death, while …

Breast cancer is the most frequent cancer in women worldwide. Despite the improvement in
diagnosis and treatments, the rates of cancer relapse and resistance to therapies remain …

Background Breast cancer (BC) is known as the most prevalent type of cancer among
women. Trastuzumab, as an anticancer drug, has been used broadly in human epidermal …